{"pmid":32418414,"title":"Expert opinion of the Working Group on Heart Failure of the Polish Cardiac Society: the patient with heart failure facing the COVID-19 pandemic.","text":["Expert opinion of the Working Group on Heart Failure of the Polish Cardiac Society: the patient with heart failure facing the COVID-19 pandemic.","New coronavirus (SARS-CoV-2, severe acute respiratory syndrome coronavirus) acute respiratory failure is the cause of the rapidly spreading coronavirus disease 2019 (COVID-19, coronavirus disease 2019), affecting thousands of people around the world. Due to the limited information on heart dysfunction in patients with COVID-19, a synthetic summary of current knowledge is needed to help clinicians who care for patients with cardiovascular disease, especially heart failure (HF) patients. We present the expert opinion of the Polish Cardiac Society - Working Group of Heart Failure (PCS - HF).","Kardiol Pol","Kaluzna-Oleksy, Marta","Gackowski, Andrzej","Jankowska, Ewa Anita","Kukulski, Tomasz","Lelonek, Malgorzata","Nessler, Jadwiga","Pawlak, Agnieszka","Rozentryt, Piotr","Rubis, Pawel","Straburzynska-Migaj, Ewa","Leszek, Przemyslaw","32418414"],"abstract":["New coronavirus (SARS-CoV-2, severe acute respiratory syndrome coronavirus) acute respiratory failure is the cause of the rapidly spreading coronavirus disease 2019 (COVID-19, coronavirus disease 2019), affecting thousands of people around the world. Due to the limited information on heart dysfunction in patients with COVID-19, a synthetic summary of current knowledge is needed to help clinicians who care for patients with cardiovascular disease, especially heart failure (HF) patients. We present the expert opinion of the Polish Cardiac Society - Working Group of Heart Failure (PCS - HF)."],"journal":"Kardiol Pol","authors":["Kaluzna-Oleksy, Marta","Gackowski, Andrzej","Jankowska, Ewa Anita","Kukulski, Tomasz","Lelonek, Malgorzata","Nessler, Jadwiga","Pawlak, Agnieszka","Rozentryt, Piotr","Rubis, Pawel","Straburzynska-Migaj, Ewa","Leszek, Przemyslaw"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418414","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.33963/KP.15359","locations":["Polish"],"countries":["Poland"],"countries_codes":["POL|Poland"],"weight":0,"_version_":1667254896800301057,"score":9.490897,"similar":[{"pmid":32463543,"title":"Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.","text":["Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.","The Coronavirus Disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and United States. This article is protected by copyright. All rights reserved.","Eur J Heart Fail","Zhang, Yuhui","Stewart Coats, Andrew J","Zheng, Zhe","Adamo, Marianna","Ambrosio, Giuseppe","Anker, Stefan D","Butler, Javed","Xu, Dingli","Mao, Jingyuan","Khan, Muhammad Shahzeb","Bai, Ling","Mebazaa, Alexandre","Ponikowski, Piotr","Tang, Qizhu","Ruschitzka, Frank","Seferovic, Petar","Tschope, Carsten","Zhang, Shuyang","Gao, Chuanyu","Zhou, Shenghua","Senni, Michele","Zhang, Jian","Metra, Marco","32463543"],"abstract":["The Coronavirus Disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and United States. This article is protected by copyright. All rights reserved."],"journal":"Eur J Heart Fail","authors":["Zhang, Yuhui","Stewart Coats, Andrew J","Zheng, Zhe","Adamo, Marianna","Ambrosio, Giuseppe","Anker, Stefan D","Butler, Javed","Xu, Dingli","Mao, Jingyuan","Khan, Muhammad Shahzeb","Bai, Ling","Mebazaa, Alexandre","Ponikowski, Piotr","Tang, Qizhu","Ruschitzka, Frank","Seferovic, Petar","Tschope, Carsten","Zhang, Shuyang","Gao, Chuanyu","Zhou, Shenghua","Senni, Michele","Zhang, Jian","Metra, Marco"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463543","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/ejhf.1915","keywords":["covid-19","coronavirus","diagnosis","heart failure","management","sars-cov2"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1668079521470873600,"score":266.92905},{"pmid":32405146,"pmcid":"PMC7217768","title":"Optimizing Access to Heart Failure Care in Canada during the COVID-19 Pandemic.","text":["Optimizing Access to Heart Failure Care in Canada during the COVID-19 Pandemic.","The traditional model of heart failure (HF) care in Canada, which relies upon a multi-disciplinary team and clinic based care processes, has been undermined as a result of the COVID-19 pandemic. As the pandemic continues, we will be challenged to improve or maintain the health status of those with HF by optimizing guideline-directed care despite physical distancing constraints and a reduction in the healthcare workforce. This will require development of new strategies specifically targeted at decreasing the risk of decompensation and resultant HF hospitalization. As such, we must quickly pivot to the adoption and application of novel technologies and revise usual care models, processes, and workflow. The unprecedented COVID-19 crisis has delivered the Canadian HF community a burning platform for the design and implementation of innovative approaches to support the vulnerable population we serve; born out of necessity, we now have the opportunity to explore innovative approaches that may inform the future of HF care delivery in Canada. Herein, we provide perspectives from leadership within the Canadian Heart Failure Society (CHFS) on how to optimize HF care during the COVID-19 pandemic.","Can J Cardiol","Virani, S A","Clarke, B","Ducharme, A","Ezekowitz, J A","Heckman, G A","McDonald, M","Mielniczuk, L M","Swiggum, E","Van Spall, H G C","Zieroth, S","32405146"],"abstract":["The traditional model of heart failure (HF) care in Canada, which relies upon a multi-disciplinary team and clinic based care processes, has been undermined as a result of the COVID-19 pandemic. As the pandemic continues, we will be challenged to improve or maintain the health status of those with HF by optimizing guideline-directed care despite physical distancing constraints and a reduction in the healthcare workforce. This will require development of new strategies specifically targeted at decreasing the risk of decompensation and resultant HF hospitalization. As such, we must quickly pivot to the adoption and application of novel technologies and revise usual care models, processes, and workflow. The unprecedented COVID-19 crisis has delivered the Canadian HF community a burning platform for the design and implementation of innovative approaches to support the vulnerable population we serve; born out of necessity, we now have the opportunity to explore innovative approaches that may inform the future of HF care delivery in Canada. Herein, we provide perspectives from leadership within the Canadian Heart Failure Society (CHFS) on how to optimize HF care during the COVID-19 pandemic."],"journal":"Can J Cardiol","authors":["Virani, S A","Clarke, B","Ducharme, A","Ezekowitz, J A","Heckman, G A","McDonald, M","Mielniczuk, L M","Swiggum, E","Van Spall, H G C","Zieroth, S"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405146","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cjca.2020.05.009","locations":["Canada","Canadian","Canada","Canada"],"countries":["Canada"],"countries_codes":["CAN|Canada"],"topics":["Prevention"],"weight":1,"_version_":1666802845417996289,"score":204.59337},{"pmid":32415767,"title":"Valvular and structural heart disease management during the COVID-19 pandemic. Expert opinion of the Working Group on Valvular Heart Diseases, the Working Group on Cardiac Surgery, and the Association of Cardiovascular Interventions of the Polish Cardiac Society.","text":["Valvular and structural heart disease management during the COVID-19 pandemic. Expert opinion of the Working Group on Valvular Heart Diseases, the Working Group on Cardiac Surgery, and the Association of Cardiovascular Interventions of the Polish Cardiac Society.","Ongoing pandemics of SARS-CoV-2 coronavirus disease 2019 (COVID-19) represents a major challenge for healthcare. Beside the proven involvement of cardiovascular system in COVID-19, increased healthcare system resources are redirected towards handling infected patients and thus induce major changes in access to services and priorities in the management of patients with unrelated chronic cardiovascular disease. This document, created by task force involving Working Groups on Valvular Heart Disease and Cardiac Surgery as well as Association of Cardiovascular Intervention, Polish Cardiac Society proposes modifications of diagnostic pathways, principles of healthcare professionals protection and guidelines for treatment according to triage and prioritization. Valvular heart teams should continue working with utilization of telemedicine and digital technology. Diagnostic tests must be simplified or deferred to minimize potentially dangerous aerosol generating procedures such as transesophageal echocardiography or exercise imaging. Treatments for aortic stenosis and mitral regurgitation have to be offered especially in urgent indications and in patients with advanced disease and poor prognosis. Expert risk stratification is essential for triage and setting the priority lists. In any case, appropriate level of personal protection must be ensured for healthcare personnel to prevent spreading infections and preserving specialized manpower to supply for the continuing need of handling chronic serious cardiovascular disease. Importantly, as soon as the local epidemic situation improves, efforts must be made to rebuild standard opportunities for elective treatment of valvular heart disease and occluder-based therapies according to existing guidelines, thus rebuilding stat-of-the-art cardiovascular services.","Kardiol Pol","Plonska-Gosciniak, Edyta","Suwalski, Piotr","Bartus, Stanislaw","Kukulski, Tomasz","Komar, Monika","Wojakowski, Wojciech","Grygier, Marek","Pruszczyk, Piotr","Gasior, Zbigniew","Huczek, Zenon","Berger-Kucza, Adrianna","Bak, Janusz","Sorysz, Danuta","Kasprzak, Jaroslaw D","32415767"],"abstract":["Ongoing pandemics of SARS-CoV-2 coronavirus disease 2019 (COVID-19) represents a major challenge for healthcare. Beside the proven involvement of cardiovascular system in COVID-19, increased healthcare system resources are redirected towards handling infected patients and thus induce major changes in access to services and priorities in the management of patients with unrelated chronic cardiovascular disease. This document, created by task force involving Working Groups on Valvular Heart Disease and Cardiac Surgery as well as Association of Cardiovascular Intervention, Polish Cardiac Society proposes modifications of diagnostic pathways, principles of healthcare professionals protection and guidelines for treatment according to triage and prioritization. Valvular heart teams should continue working with utilization of telemedicine and digital technology. Diagnostic tests must be simplified or deferred to minimize potentially dangerous aerosol generating procedures such as transesophageal echocardiography or exercise imaging. Treatments for aortic stenosis and mitral regurgitation have to be offered especially in urgent indications and in patients with advanced disease and poor prognosis. Expert risk stratification is essential for triage and setting the priority lists. In any case, appropriate level of personal protection must be ensured for healthcare personnel to prevent spreading infections and preserving specialized manpower to supply for the continuing need of handling chronic serious cardiovascular disease. Importantly, as soon as the local epidemic situation improves, efforts must be made to rebuild standard opportunities for elective treatment of valvular heart disease and occluder-based therapies according to existing guidelines, thus rebuilding stat-of-the-art cardiovascular services."],"journal":"Kardiol Pol","authors":["Plonska-Gosciniak, Edyta","Suwalski, Piotr","Bartus, Stanislaw","Kukulski, Tomasz","Komar, Monika","Wojakowski, Wojciech","Grygier, Marek","Pruszczyk, Piotr","Gasior, Zbigniew","Huczek, Zenon","Berger-Kucza, Adrianna","Bak, Janusz","Sorysz, Danuta","Kasprzak, Jaroslaw D"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415767","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.33963/KP.15358","locations":["Polish"],"countries":["Poland"],"countries_codes":["POL|Poland"],"topics":["Prevention"],"weight":1,"_version_":1666994545911398400,"score":199.98326},{"pmid":32405232,"pmcid":"PMC7219367","title":"Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic.","text":["Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic.","Background: The coronavirus disease 2019 (COVID-19) pandemic has increased burden on healthcare systems with subsequent reductions in non-emergent hospitalizations and procedures. While there are widespread reports of intentional reductions in elective hospitalizations, trends in urgent or emergent hospitalizations including heart failure (HF) hospitalizations have not been adequately characterized. Methods: We evaluated trends of HF hospitalizations before and during the COVID-19 pandemic at the University of Mississippi Medical Center using electronic health records and discharge database. We also compared HF hospitalization trends during the same time frame in 2019 to account for seasonal variation in HF presentations. Results: Prior to the COVID-19 pandemic in our medical center, a mean of 30 patients per week were admitted with a principal diagnosis of HF. After the first case of COVID-19 was diagnosed in Mississippi, there was a sharp 50% decline in the number of HF hospitalizations that declined even further after a \"state of emergency\" was declared in Mississippi. Conclusions: Based on observations from a large academic medical center, there has been a significant reduction in the number of patients hospitalized for HF during the COVID-19 pandemic. Further investigation of these trends is warranted to determine the effects of the COVID-19 pandemic on long-term HF outcomes.","J Card Fail","Hall, Michael E","Vaduganathan, Muthiah","Khan, Muhammad Shahzeb","Papadimitriou, Lampros","Long, Robert C","Hernandez, Gabriel A","Moore, Charles K","Lennep, Brandon W","McMullan, Michael R","Butler, Javed","32405232"],"abstract":["Background: The coronavirus disease 2019 (COVID-19) pandemic has increased burden on healthcare systems with subsequent reductions in non-emergent hospitalizations and procedures. While there are widespread reports of intentional reductions in elective hospitalizations, trends in urgent or emergent hospitalizations including heart failure (HF) hospitalizations have not been adequately characterized. Methods: We evaluated trends of HF hospitalizations before and during the COVID-19 pandemic at the University of Mississippi Medical Center using electronic health records and discharge database. We also compared HF hospitalization trends during the same time frame in 2019 to account for seasonal variation in HF presentations. Results: Prior to the COVID-19 pandemic in our medical center, a mean of 30 patients per week were admitted with a principal diagnosis of HF. After the first case of COVID-19 was diagnosed in Mississippi, there was a sharp 50% decline in the number of HF hospitalizations that declined even further after a \"state of emergency\" was declared in Mississippi. Conclusions: Based on observations from a large academic medical center, there has been a significant reduction in the number of patients hospitalized for HF during the COVID-19 pandemic. Further investigation of these trends is warranted to determine the effects of the COVID-19 pandemic on long-term HF outcomes."],"journal":"J Card Fail","authors":["Hall, Michael E","Vaduganathan, Muthiah","Khan, Muhammad Shahzeb","Papadimitriou, Lampros","Long, Robert C","Hernandez, Gabriel A","Moore, Charles K","Lennep, Brandon W","McMullan, Michael R","Butler, Javed"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405232","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cardfail.2020.05.005","keywords":["covid-19","coronavirus 2019","heart failure"],"locations":["Mississippi","Mississippi"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666802845393879041,"score":193.48949},{"pmid":32482087,"title":"Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark: A Nationwide Cohort Study.","text":["Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark: A Nationwide Cohort Study.","BACKGROUND: The Danish government ordered a public lockdown on March 12, 2020, because of the coronavirus disease 2019 (COVID-19) pandemic. We investigated the immediate consequences of such a lockdown for patients with heart failure (HF). METHODS: Using the Danish nationwide administrative databases, we investigated the incidence of new-onset HF and hospitalizations for worsening HF before and after the lockdown (January 1 to March 11 versus March 12 to March 31) in 2020 versus 2019. We also investigated the mortality for all patients with HF and in COVID-19-infected patients with HF. RESULTS: Rates of new-onset HF between January 1 and March 11 were comparable for 2020 and 2019 (1.83 versus 1.78 per 10 000 person-years; P=0.19), while hospitalizations for worsening HF were slightly higher in 2020 versus 2019 (1.04 versus 0.93 per 1000 person-years; P=0.02). In the lockdown period, rates of new-onset HF diagnoses (1.26 versus 2.25 per 1000 person-years) and of hospitalizations for worsening HF (0.63 versus 0.99 per 1000 person-years) were significantly lower in 2020 versus 2019 (P for both, <0.0001). Mortality was similar before and after the national lockdown for the population with HF. We observed 90 HF patients with diagnosed COVID-19 infection, of whom 37% (95% CI, 23%-50%) died within 15 days. CONCLUSIONS: The number of patients hospitalized with worsening HF or diagnosed with new-onset HF was markedly reduced after lockdown but has not yet impacted mortality in HF patients at a population-based level. However, these data raise concerns for a potential undertreatment of HF currently that may impact prognosis in the longer term.","Circ Heart Fail","Andersson, Charlotte","Gerds, Thomas","Fosbol, Emil","Phelps, Matthew","Andersen, Julie","Lamberts, Morten","Holt, Anders","Butt, Jawad H","Madelaire, Christian","Gislason, Gunnar","Torp-Pedersen, Christian","Kober, Lars","Schou, Morten","32482087"],"abstract":["BACKGROUND: The Danish government ordered a public lockdown on March 12, 2020, because of the coronavirus disease 2019 (COVID-19) pandemic. We investigated the immediate consequences of such a lockdown for patients with heart failure (HF). METHODS: Using the Danish nationwide administrative databases, we investigated the incidence of new-onset HF and hospitalizations for worsening HF before and after the lockdown (January 1 to March 11 versus March 12 to March 31) in 2020 versus 2019. We also investigated the mortality for all patients with HF and in COVID-19-infected patients with HF. RESULTS: Rates of new-onset HF between January 1 and March 11 were comparable for 2020 and 2019 (1.83 versus 1.78 per 10 000 person-years; P=0.19), while hospitalizations for worsening HF were slightly higher in 2020 versus 2019 (1.04 versus 0.93 per 1000 person-years; P=0.02). In the lockdown period, rates of new-onset HF diagnoses (1.26 versus 2.25 per 1000 person-years) and of hospitalizations for worsening HF (0.63 versus 0.99 per 1000 person-years) were significantly lower in 2020 versus 2019 (P for both, <0.0001). Mortality was similar before and after the national lockdown for the population with HF. We observed 90 HF patients with diagnosed COVID-19 infection, of whom 37% (95% CI, 23%-50%) died within 15 days. CONCLUSIONS: The number of patients hospitalized with worsening HF or diagnosed with new-onset HF was markedly reduced after lockdown but has not yet impacted mortality in HF patients at a population-based level. However, these data raise concerns for a potential undertreatment of HF currently that may impact prognosis in the longer term."],"journal":"Circ Heart Fail","authors":["Andersson, Charlotte","Gerds, Thomas","Fosbol, Emil","Phelps, Matthew","Andersen, Julie","Lamberts, Morten","Holt, Anders","Butt, Jawad H","Madelaire, Christian","Gislason, Gunnar","Torp-Pedersen, Christian","Kober, Lars","Schou, Morten"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482087","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1161/CIRCHEARTFAILURE.120.007274","keywords":["heart failure","hospitalization","incidence","infections"],"locations":["Danish","Danish","Denmark"],"countries":["Denmark"],"countries_codes":["DNK|Denmark"],"topics":["Prevention"],"weight":1,"_version_":1668532114912444416,"score":176.82047}]}